Puma Biotechnology Inc - Common Stock — Quarterly Cash Flow (NASDAQ:PBYI) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 213.33 M196.18 M194.92 M202.86 M216.3 M192.7 M Total liabilities 121.21 M99.07 M90.2 M87.59 M85.96 M64.28 M Total equity 92.13 M97.11 M104.72 M115.27 M130.34 M128.42 M Total liabilities & shareholders' equities 213.33 M196.18 M194.92 M202.86 M216.3 M192.7 M Total debt 21.72 M10.65 M44.87 M33.72 M22.52 M11.28 M Net debt -65.12 M-71.47 M-77.87 M-88.42 M-91.63 M-80.38 M

Puma Biotechnology Inc - Common Stock

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

News

PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call Transcript

Puma Biotechnology, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:PBYI) 2026-05-08

Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?

Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why

IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?

PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View

Puma Biotechnology, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) 2026-02-27

Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates